ClinicalTrials.gov
ClinicalTrials.gov Menu

Protein Supply in Elderly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01317511
Recruitment Status : Completed
First Posted : March 17, 2011
Last Update Posted : March 17, 2011
Sponsor:
Information provided by:
Maastricht University Medical Center

Brief Summary:
Stimulating overnight muscle protein synthesis, might augment muscle hypertrophy, increase mitochondrial mass, and/or improve muscle tissue repair. The goal of this proposal will be to provide further insight into the responsiveness of the muscle protein synthetic machinery to food intake in relation to age.

Condition or disease Intervention/treatment Phase
Muscle Synthesis Dietary Supplement: Protein Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Overnight Protein Supply as a Dietary Strategy to Improve Muscle Mass in Elderly.
Study Start Date : June 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : February 2011

Arm Intervention/treatment
Experimental: Protein
Protein drink
Dietary Supplement: Protein
Protein drink
Other Name: casein vs water
Placebo Comparator: Placebo
water
Dietary Supplement: Protein
Protein drink
Other Name: casein vs water



Primary Outcome Measures :
  1. Protein synthesis [ Time Frame: overnight (12 h) ]
    Overnight protein synthesis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males
  • Age between 65 and 80 years
  • BMI < 30 kg/m2

Exclusion Criteria:

  • Type 2 diabetic patients
  • Use of medication
  • All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. artrosis, arthritis, spasticity/rigidity, all neurological disorders and paralysis).
  • Use of anticoagulants, blood diseases, allergy for lidocain.
  • Contra indications for the use of a nasogastric tube: high risk of aspiration, gastric stasis, gastro-oesophageal reflux, upper gastrointestinal stricture, nasal injuries and base of skull fractures.
  • Patients suffering from PKU (Phenylketonuria).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01317511


Locations
Netherlands
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6229ER
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Luc van Loon, Prof. Maastricht UMC

Responsible Party: Prof. LJC van Loon, MaastrichtUMC
ClinicalTrials.gov Identifier: NCT01317511     History of Changes
Other Study ID Numbers: MEC 09-3-078.3
First Posted: March 17, 2011    Key Record Dates
Last Update Posted: March 17, 2011
Last Verified: March 2011